Literature DB >> 25416323

Increased serum levels of interleukin-8 in patients with tension-type headache.

Renan B Domingues1, Halina Duarte2, Natália P Rocha3, Antonio L Teixeira4.   

Abstract

BACKGROUND AND OBJECTIVES: The pathophysiology of tension-type headache is not well understood. Increased peripheral levels of pro-inflammatory cytokines may act as mediators of several chronic pain disorders. The aim of the present study was to investigate the peripheral levels of chemokines in patients with tension-type headache.
METHODS: This was a cross sectional study evaluating serum levels of chemokines in age and sex-matched tension-type headache patients, ictally and interictally, and control participants. Beck Depression and Anxiety Inventories were recorded. Serum levels of monocyte chemoattractant protein-1, macrophage inflammatory protein 1α, regulated on activation, normal T cell expressed and secreted, eotaxin, eotaxin-2, interleukin-8, interferon gamma induced protein-10 were measured by enzyme-linked immunosorbent assay.
RESULTS: A total of 96 participants (48 tension-type headache, 48 controls) were included. Interleukin-8 levels were significantly increased in patients with tension-type headache when compared to controls (413.8 (123.4-1756.3) and 329 (107.8-955.6), respectively, P = 0.025). Anxiety and depression scores were higher in patients with tension-type headache but interleukin-8 increase in tension-type headache patients persisted after controlling for anxiety and depression symptoms. Patients with headache at the time of assessment had increased monocyte chemoattractant protein-1 levels when compared with patients without headache (2809.3 (1101-6122.2) and 1630.2 (669.3-31056.8), respectively P = 0.026). Patients with episodic and chronic tension-type headache had no significant differences in serum chemokines levels.
CONCLUSION: Interleukin-8 was increased in tension-type headache and monocyte chemoattractant protein-1 was higher in tension-type headache patients with headache, suggesting that pro-inflammatory mechanisms may participate in tension-type headache pathophysiology. © International Headache Society 2014.

Entities:  

Keywords:  Tension-type headache; anxiety; chemokines; chronic tension-type headache; depression; episodic tension-type headache; inflammation

Mesh:

Substances:

Year:  2014        PMID: 25416323     DOI: 10.1177/0333102414559734

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  5 in total

Review 1.  Acupoints for Tension-Type Headache: A Literature Study Based on Data Mining Technology.

Authors:  Lingyun Lu; Qian Wen; Xinyu Hao; Qianhua Zheng; Ying Li; Ning Li
Journal:  Evid Based Complement Alternat Med       Date:  2021-03-12       Impact factor: 2.629

2.  Cytokine and interleukin profile in patients with headache and COVID-19: A pilot, CASE-control, study on 104 patients.

Authors:  Javier Trigo; David García-Azorín; Álvaro Sierra-Mencía; Álvaro Tamayo-Velasco; Pedro Martínez-Paz; Eduardo Tamayo; Angel Luis Guerrero; Hugo Gonzalo-Benito
Journal:  J Headache Pain       Date:  2021-06-04       Impact factor: 7.277

Review 3.  Headache and immunological/autoimmune disorders: a comprehensive review of available epidemiological evidence with insights on potential underlying mechanisms.

Authors:  Leonardo Biscetti; Gioacchino De Vanna; Elena Cresta; Ilenia Corbelli; Lorenzo Gaetani; Letizia Cupini; Paolo Calabresi; Paola Sarchielli
Journal:  J Neuroinflammation       Date:  2021-11-08       Impact factor: 8.322

4.  Evaluation of Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and C-Reactive Protein in Tension-Type Headache Patients.

Authors:  Hasan Hüseyin Özdemir; Ahmet Dönder
Journal:  J Neurosci Rural Pract       Date:  2021-06-15

5.  Loss of Microglia and Impaired Brain-Neurotrophic Factor Signaling Pathway in a Comorbid Model of Chronic Pain and Depression.

Authors:  Cuizhen Zhu; Jinjie Xu; Yezhe Lin; Peijun Ju; Dongxia Duan; Yanjia Luo; Wenhua Ding; Shengnan Huang; Jinghong Chen; Donghong Cui
Journal:  Front Psychiatry       Date:  2018-10-04       Impact factor: 4.157

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.